SC
SAGE

Schubert & Co’s Sage Therapeutics SAGE Stock Holding History

Schubert & Co’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-31
Closed -$1.3K – 1223
2023
Q1 		$1.3K Hold
31
– – ﹤0.01% 1087
2022
Q4 		$1.18K Sell
31
-10
-24% -$382 ﹤0.01% 1109
2022
Q3 		$2K Buy
41
+27
+193% +$1.04K ﹤0.01% 899
2022
Q2 		$0 Buy
14
+10
+250% +$335 ﹤0.01% 1573
2022
Q1 		$0 Buy
4
+2
+100% +$75 ﹤0.01% 1302
2021
Q4 		$0 Buy
+2
New +$84 ﹤0.01% 1247

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Schubert & Co's SAGE Position: Q2 2023 in Review

Schubert & Co sold out of Sage Therapeutics (SAGE) in Q2 2023, closing a stake of 31 shares — an estimated $1.3K sold.

Schubert & Co first reported a position in SAGE in Q4 2021 and held it in 6 quarters. The position peaked at $2K in Q3 2022. 225 funds tracked by Wall St. Rank hold SAGE as of Q2 2023.

  • Schubert & Co reported no remaining Sage Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Schubert & Co sold 31 Sage Therapeutics shares in Q2 2023, an estimated $1.3K.
  • Schubert & Co first reported a position in Sage Therapeutics in Q4 2021 and held it in 6 quarters.
  • Schubert & Co's Sage Therapeutics position peaked at $2K in Q3 2022.
  • 225 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.